NASDAQ:NBIX - Neurocrine Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$108.46 -0.71 (-0.65 %)
(As of 10/23/2018 02:43 PM ET)
Previous Close$109.17
Today's Range$105.50 - $108.46
52-Week Range$57.74 - $126.98
Volume34,341 shs
Average Volume888,606 shs
Market Capitalization$10.13 billion
P/E Ratio-66.07
Dividend YieldN/A
Beta0.55
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
Previous Symbol
CUSIP64125C10
Phone858-617-7600

Debt

Debt-to-Equity Ratio1.00
Current Ratio9.19
Quick Ratio9.19

Price-To-Earnings

Trailing P/E Ratio-66.07
Forward P/E Ratio723.07
P/E Growth36

Sales & Book Value

Annual Sales$161.63 million
Price / Sales60.71
Cash FlowN/A
Price / CashN/A
Book Value$4.21 per share
Price / Book25.76

Profitability

EPS (Most Recent Fiscal Year)($1.62)
Net Income$-142,540,000.00
Net Margins-16.07%
Return on Equity-14.22%
Return on Assets-6.42%

Miscellaneous

Employees400
Outstanding Shares90,470,000
Market Cap$10.13 billion
OptionableN/A

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its earnings results on Tuesday, July, 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.11. The business had revenue of $96.90 million for the quarter, compared to the consensus estimate of $84.11 million. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. Neurocrine Biosciences's quarterly revenue was up 1428.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.68) earnings per share. View Neurocrine Biosciences' Earnings History.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, November 5th 2018. View Earnings Estimates for Neurocrine Biosciences.

How can I listen to Neurocrine Biosciences' earnings call?

Neurocrine Biosciences will be holding an earnings conference call on Monday, November 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8778769176.

What price target have analysts set for NBIX?

18 Wall Street analysts have issued 1 year target prices for Neurocrine Biosciences' stock. Their predictions range from $79.00 to $162.00. On average, they anticipate Neurocrine Biosciences' share price to reach $122.2222 in the next twelve months. This suggests a possible upside of 14.2% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

What is the consensus analysts' recommendation for Neurocrine Biosciences?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

What are Wall Street analysts saying about Neurocrine Biosciences stock?

Here are some recent quotes from research analysts about Neurocrine Biosciences stock:
  • 1. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month PT of $150 on NBIX. On Tuesday, we hosted a call with a physician who has deep expertise in movement disorders and is familiar with, arguably pioneered, the use of VMAT2 inhibitors in various hyperkinetic disorders, having treated thousands of pediatric Tourette Syndrome (pTS) patients. Our discussion focused on the KOL’s views on the current TS treatment landscape, unmet needs, and efficacy of VMAT2i’s. Although some investors may be skeptical of valbenazine efficacy in pTS after 2 prior study failures (one in adult and another in pTS), we are optimistic about PoS of the ongoing pTS trial. Based, in part, on our recent KOL diligence including this call, we have increased conviction in not only the probability of T-Force GOLD success, but also in the market opportunity for valbe’ in TS." (9/14/2018)
  • 2. Needham & Company LLC analysts commented, "Mesoblast announced good news that remestemcel-L (MSC-100-IV) met the primary endpoint in a Phase III trial to treat steroid-refractory acute graft- versus-host disease (GvHD)." (2/22/2018)

Who are some of Neurocrine Biosciences' key competitors?

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 60)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 38)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 60)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 53)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 61)

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Handelsbanken Fonder AB (0.18%), Bank of Montreal Can (0.07%), Aperio Group LLC (0.03%), Seven Eight Capital LP (0.03%), EFG Asset Management Americas Corp. (0.02%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Stephen A Sherwin, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Which institutional investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Woodstock Corp. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Stephen A Sherwin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

Which institutional investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Seven Eight Capital LP, EFG Asset Management Americas Corp., Nisa Investment Advisors LLC, Mizuho Securities USA LLC, Sumitomo Life Insurance Co., Handelsbanken Fonder AB and Fox Run Management L.L.C.. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $107.0255.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $10.13 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is http://www.neurocrine.com.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)

Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  707 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  876
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel